908 Devices Inc. (MASS)

Over the past six months, 908 Devices, Inc. stock has been impacted by product enhancements, financial results announcements, and participation in investor conferences. The United States Coast Guard purchased the company's handheld mass spectrometry devices. Insider transactions, including equity compensation and stock sales, occurred. As of February 4, 2026, the share price was $6.32, a 138.49% increase from February 5, 2025. The 52-week high was $9.34 and the 52-week low was $1.92.

Demand for 908 Devices, Inc.'s products exhibits variability, particularly concerning government contracts. The company's business model involves initial device sales and recurring revenue from consumables, service contracts, and software subscriptions. Government procurement cycles, installed base growth, and product development influence demand patterns. Government funding delays can affect revenue recognition, and the company must continuously innovate to remain competitive.

908 Devices, Inc. is a technology company specializing in handheld and desktop mass spectrometry devices for chemical and biochemical analysis, operating in the medical and measuring devices sectors. In March 2025, the company divested its bioprocessing desktop product portfolio to Repligen Corporation for $70 million, focusing on handheld chemical detection for public safety and defense. Key products include the MX908, XplorIR, VipIR, ProtectIR, ThreatID, Rebel, Maverick, Maven, Trace C2, and ZipChip solution.

908 Devices, Inc. operates globally, with its products and services reaching the United States, Europe, the Middle East, Africa, the Asia Pacific, and the rest of the Americas. The company is headquartered in Burlington, Massachusetts, and has consolidated its handheld product manufacturing into an expanded facility in Danbury, Connecticut. It also has a life science R&D facility in Morrisville, NC, and a bioanalytics R&D facility in Braunschweig, Germany.

908 Devices, Inc. is known for revolutionizing chemical analysis with simple, smart, and speedy mass spectrometry technology. The company's brand reputation has been positively impacted by the strategic pivot to focus on handheld chemical detection, continuous product innovation, strong financial performance, and key orders from entities like the United States Coast Guard.

Institutional investors hold approximately 88.06% of 908 Devices Inc.'s shares, with major holders including AWM Investment Company, Inc., First Light Asset Management, LLC, and State Street Corp. Individual insiders hold about 8.4% of the company's shares. CEO Kevin J. Knopp directly held 795,968 shares, with an additional 541,223 shares held indirectly. Insiders have sold more stock than they have bought in the past three months, with sales totaling $143,222.00.